● Recruiting

To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer

Condition: Renal Cell Carcinoma (RCC) · Sponsor: Hrain Biotechnology Co., Ltd.

PhasePhase 1

Planned participants18

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersNo

About this study

This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability and pharmacokinetic(PK) profiles of the investigational agent, and preliminarily assess its efficacy in subjects with advanced/metastatic renal cell carcinoma, and determine the recommended dose and infusion regimen for Phase 2 trials.

This description comes directly from the study's public registry record.

Talk to the study team

Fang Xiang · 86-21-58552006 · xiangfang@dashengbio.com

Always discuss trial participation with your own doctor first.

Locations (1)

RenJi Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07647744